[go: up one dir, main page]

WO2001058410A3 - A method of treating colon cancer by administering apigenin, luteolin, diosmetin and crysin - Google Patents

A method of treating colon cancer by administering apigenin, luteolin, diosmetin and crysin Download PDF

Info

Publication number
WO2001058410A3
WO2001058410A3 PCT/US2001/004656 US0104656W WO0158410A3 WO 2001058410 A3 WO2001058410 A3 WO 2001058410A3 US 0104656 W US0104656 W US 0104656W WO 0158410 A3 WO0158410 A3 WO 0158410A3
Authority
WO
WIPO (PCT)
Prior art keywords
chrysin
administering
glucuronosyltransferase
udp
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/004656
Other languages
French (fr)
Other versions
WO2001058410A2 (en
Inventor
Thomas Walle
Perry V Halushka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Priority to AU2001236982A priority Critical patent/AU2001236982A1/en
Publication of WO2001058410A2 publication Critical patent/WO2001058410A2/en
Publication of WO2001058410A3 publication Critical patent/WO2001058410A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a method of treating any condition of elevated levels of unconjugated bilirubin in adults or children, such as Gilbert's syndrome or liver cirrhosis. The method calls for the administration of chrysin or chrysin analogs via dietary or other means. Also provided is a method of increasing glucuronidation of bilirubin in a subject, comprising administering to the subject an amount of chrysin effective to increase the glucuronidation of bilirubin. A method of increasing the expression of UDP-glucuronosyltransferase in a subject is provided, comprising administering to the subject an amount of chrysin effective to increase the UDP-glucuronosyltransferase. Upregulation of the expression of UDP-glucuronosyltransferase levels is expected to be beneficial in a number of areas: 1) increased detoxification of ingested carcinogens, such as the cooked-food mutagens (chrysin is an aromatase inhibitor in cells); 2) decreasing the conversion of androgens to estrogens, potentially building muscle mass or for prevention of breast cancer in women. In the method of upregulating UGT, UDP-glucuronosyltransferase can be a UGT1A isoform. A method of treating colon cancer is provided, comprising administering an effective amount of a flavone, whereby the administration of the flavone treats the colon cancer.
PCT/US2001/004656 2000-02-11 2001-02-12 A method of treating colon cancer by administering apigenin, luteolin, diosmetin and crysin Ceased WO2001058410A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001236982A AU2001236982A1 (en) 2000-02-11 2001-02-12 A method of treating colon cancer by administering apigenin, luteolin, diosmetinand crysin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18207200P 2000-02-11 2000-02-11
US60/182,072 2000-02-11
US23277100P 2000-09-15 2000-09-15
US60/232,771 2000-09-15

Publications (2)

Publication Number Publication Date
WO2001058410A2 WO2001058410A2 (en) 2001-08-16
WO2001058410A3 true WO2001058410A3 (en) 2002-01-24

Family

ID=26877757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004656 Ceased WO2001058410A2 (en) 2000-02-11 2001-02-12 A method of treating colon cancer by administering apigenin, luteolin, diosmetin and crysin

Country Status (2)

Country Link
AU (1) AU2001236982A1 (en)
WO (1) WO2001058410A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105725A1 (en) * 2005-04-05 2006-10-12 Shanghai Gloriayx Biopharmaceuticals Co., Ltd A combination of luteolin and one of pt chemotherapeutics
GB201407694D0 (en) * 2014-05-01 2014-06-18 Univ Montfort Compound
CN104208598A (en) * 2014-09-26 2014-12-17 禤燕华 Chinese medicinal composition for treating chronic jaundice
CN106389405A (en) * 2015-07-30 2017-02-15 中国科学院大连化学物理研究所 A class of glucuronosyltransferase UGT1A1 inducers and applications thereof
CN114053414A (en) * 2021-12-31 2022-02-18 大连医科大学 Application of a flavonoid USP22 inhibitor in the preparation of anti-tumor immune drugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5858371A (en) * 1997-02-05 1999-01-12 Panacea Biotech Limited Pharmaceutical composition for the control and treatment of anorectal and colonic diseases
WO1999021550A1 (en) * 1997-10-24 1999-05-06 Bio-Monde Preparations Limited Use of coumarin derivatives for the treatment of digestive tract disorders
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5858371A (en) * 1997-02-05 1999-01-12 Panacea Biotech Limited Pharmaceutical composition for the control and treatment of anorectal and colonic diseases
WO1999021550A1 (en) * 1997-10-24 1999-05-06 Bio-Monde Preparations Limited Use of coumarin derivatives for the treatment of digestive tract disorders
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KLOSS J.: "Back to Eden", March 1972, BEREFICIAL BOOKS, NEW YORK, US, XP002943606 *

Also Published As

Publication number Publication date
AU2001236982A1 (en) 2001-08-20
WO2001058410A2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
BG104727A (en) Pharmaceutical composition of topiramate
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
ATE264102T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE WITH RAPID TRANSMUCOSAL ABSORPTION
SG152270A1 (en) Immunemodulating oligosaccharides
WO2003055444A3 (en) Resveratrol analogues
EP1248629A4 (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
IL151314A0 (en) Micelles, methods for their preparation and methods for delivery of micelles to patients
WO2001058410A3 (en) A method of treating colon cancer by administering apigenin, luteolin, diosmetin and crysin
HUP0003546A3 (en) Compositions for administering taxanes orally to human patients
HUP0203303A3 (en) Compositions for administering taxanes orally to human patients
NO20021160D0 (en) constituents
EP0965344A4 (en) Prophylactic and therapeutic agent for inflammatory intestinal diseases
EP1219630A4 (en) Immunopotentiating compositions
SE8500996D0 (en) METHOD OF TREATMENT
NZ326345A (en) Composition containing diosgenin
BR0107960A (en) Treatment of allergic and inflammatory conditions
BR0212249A (en) Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, and use of a compound
EP1136492A4 (en) Sulfonamide compounds and uses thereof as medicines
EE04264B1 (en) Use of Sodium Chloride in the Preparation of a Substance to Reduce Gastrointestinal Side Effects Due to Administration of Camptothecin Derivatives
AU2002366645A8 (en) Compositions for the treatment of lupus, other rheumatic diseases and joint diseases
ATE429826T1 (en) COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ALTERED BONE METABOLISM
NZ505933A (en) Incorporation of cholesterol lowering agents into confectionery dosage forms
Matsukawa et al. High biliary excretion levels of quercetin metabolites after administration of a quercetin glycoside in conscious bile duct cannulated rats
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP